Paul Wotton

Combined Therapeutics, Inc. engages in biotechnology industry group. The company was founded by Romain Micol, Robert Langer, and Dan Anderson in and is headquartered in North Cambridge, MA.

Combined Therapeutics, Inc. engages in biotechnology industry group. The company was founded by Romain Micol, Robert Langer, and Dan Anderson in and is headquartered in North Cambridge, MA.

eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA.

Kytopen Corp. engages in the provision of technology solutions. It develops genetically engineered cells that modifies microorganisms. The company was founded by Paulo A. Gracia and Cullen R. Buie in 2017 and is headquartered in Cambridge, MA.

The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010.

eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA.

Dimension Inx LLC operates as a regenerative medicine company. It offers 3D-Printing for tissue and organ repair and regeneration. The company was founded by Ramille N. Shah, Caralynn Nowinski Collens and Adam E. Jakus in 2016 and is headquartered in Chicago, IL.

eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA.

Combined Therapeutics, Inc. engages in biotechnology industry group. The company was founded by Romain Micol, Robert Langer, and Dan Anderson in and is headquartered in North Cambridge, MA.

Combined Therapeutics, Inc. engages in biotechnology industry group. The company was founded by Romain Micol, Robert Langer, and Dan Anderson in and is headquartered in North Cambridge, MA.

Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.

Dimension Inx LLC operates as a regenerative medicine company. It offers 3D-Printing for tissue and organ repair and regeneration. The company was founded by Ramille N. Shah, Caralynn Nowinski Collens and Adam E. Jakus in 2016 and is headquartered in Chicago, IL.

Dimension Inx LLC operates as a regenerative medicine company. It offers 3D-Printing for tissue and organ repair and regeneration. The company was founded by Ramille N. Shah, Caralynn Nowinski Collens and Adam E. Jakus in 2016 and is headquartered in Chicago, IL.

Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation.